Relmada Therapeutics is working toward the launch, next year, of a Phase 2 clinical trial to test sepranolone —…
Articles by Steve Bryson, PhD
People with Prader-Willi Syndrome (PWS) experience worse depression, overall health, and life satisfaction compared with the general population, according…
The extended-release formulation of diazoxide choline (DCCR) — approved in the U.S. earlier this year for use in…
The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether to approve Soleno…
Hospitalizations among people with Prader-Willi syndrome (PWS) are characterized by higher healthcare utilization and complexity compared with non-PWS patients,…
Neuren Pharmaceuticals has opened the first site for a U.S.-based Phase 2 clinical trial of its investigational therapy NNZ-2591…
EMO-T, a new emotional skill training program, helped children with Prader-Willi syndrome (PWS) express, recognize, understand, and regulate emotions,…
Reduced activity of the Magel2 gene, which is defective in Prader-Willi syndrome (PWS), specifically in nerve cells that supply…
A Phase 2 study evaluating ARD-101, an investigational, gut-targeting Prader-Willi syndrome (PWS) oral therapy, is now enrolling up to…
Adolescents and adults with Prader-Willi syndrome (PWS) say they struggle with constant hunger and the urge to seek food,…